Sutro Biopharma Adds $16.5M

South San Francisco-based Sutro Biopharma, which develops a scalable biochemical protein synthesis platform, said today that it has added $16.5M in a second tranche of its Series C funding round. The round was led by Skyline Ventures, and also included prior investors Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. The company said it has now raised $36.5M in the round. The company said it has raised $60 million since its founding in 2003. Sutro is led by William Newell, and is targeting its products at cancer therapies. More information »